Groundbreaking Clinical Research
The Montefiore Einstein Center for Cancer Care, and our research partner, Albert Einstein Cancer Center, a National Cancer Institute-designated Cancer Center, share a vigorous commitment to the power of research to improve technologies, therapies and, most important, patient outcomes.
In so doing, we hope to accelerate the pace at which promising new discoveries become the proven treatments and protocols of today and tomorrow. The distinguished, forward-thinking oncologists and hematologists on our stem cell transplant team have numerous and unique clinical, translational and basic studies in progress at all times.
Among our many other endeavors, we are currently:
- Pioneering an advanced, more effective and less toxic treatment study, in which chemotherapy is given in a "personalized fashion," based on an individual's own drug metabolism and subsequent internal medication levels.
- Evaluating several strategies to decrease those post-transplant infections that can sometimes prolong or, at worst, derail recovery.
- Spearheading new treatments and clinical trials though our dedicated center for patients with myelodysplastic syndromes (www.mdstreatment.com). The clinical trials offered include combination therapies with epigenetic drugs and newer agents. We offer a combination of eltrombopag (an agent that raises platelets) and lenalidomide (a drug effective in MDS) to patients with low platelets who are ineligible for many other therapies (ClinicalTrials.gov identifier: NCT01772420). We also offer Rigosertib, a promising drug, for patients that have failed treatments with Vidaza (Clinical trials.gov identifier: NCT01241500).
- Studying monoclonal antibody therapy for relapsed acute lymphocytic leukemia that has "Trojan Horse" poison specifically targeted to the leukemia cell. Montefiore is the only place worldwide that offers this dual chemoimmunotherapy.
We invite you to meet our specialized team and explore the wealth of groundbreaking stem cell and leukemia research and initiatives at Montefiore, including clinical trials.